SMMT Stock Financial Analysis - Summit Therapeutics Inc. (NasdaqGM) Stock

Overview

Summit Therapeutics Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of patient, physician, caregiver, and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. The Company’s pipeline of product candidates is designed with the goal to become the patient-friendly, new-era standard-of-care medicines, in the therapeutic area of oncology.

Quality, Value, Momentum Scores

This card shows the Quality, Value, and Momentum scores for the company

Quality

The QualityScore is a proprietary scoring model that identifies high quality companies, based on cash generating efficiencies.

Value

Proprietary scoring model that ranks companies based on their relative valuation. Scores range from 0 to 100, with 100 being the most undervalued.

Momentum

Proprietary scoring model that ranks companies on their six-month momentum.

Fund Sentiment

The Fund Sentiment (fka Ownership) score is a proprietary quantitative model that ranks companies based on levels of ownership accumulation.

QVM

The QVM Score is a proprietary scoring model that combines Quality, Value, and Momentum into a single metric that ranks companies from 0 to 100.

Income Statement: Revenue, Operating Income, Net Income

The operating income for Summit Therapeutics Inc. as of June 30, 2025 is -759.28 MM.
The net income for Summit Therapeutics Inc. as of June 30, 2025 is -746.08 MM.

Period End (TTM)	Revenue (MM)	Operating Income (MM)	Net Income (MM)
2025-06-30		-759.28	-746.08
2025-03-31		-235.45	-240.75
2024-12-31		-210.99	-221.31
2024-09-30		-181.59	-196.68
2024-06-30		-143.70	-161.69
2024-03-31		-114.89	-116.03
2023-12-31		-88.73	-614.93
2023-09-30	0.00	-65.62	-597.59
2023-06-30	0.22	-62.07	-597.71
2023-03-31	0.46	-58.97	-599.76
2022-12-31	0.70	-63.62	-78.78
2022-09-30	0.96	-77.84	-86.65
2022-06-30	2.04	-80.38	-84.87
2022-03-31	1.87	-91.42	-92.51
2021-12-31	1.81	-86.19	-88.60
2021-09-30	1.74	-71.69	-75.04
2021-06-30	0.61	-68.29	-73.19
2021-03-31	0.73	-59.92	-64.05
2020-12-31	0.86	-52.33	-52.70
2020-09-30	0.69	-50.92	-50.89

Income Statement: EPS

The earnings per share basic for Summit Therapeutics Inc. as of June 30, 2025 is -1.01.
The earnings per share diluted for Summit Therapeutics Inc. as of June 30, 2025 is -1.01.

Period End (TTM)	Earnings Per Share Basic	Earnings Per Share Diluted
2025-06-30	-1.01	-1.01
2025-03-31	-0.33	-0.34
2024-12-31	-0.31	-0.31
2024-09-30	-0.28	-0.27
2024-06-30	-0.23	-0.23
2024-03-31	-0.17	-0.16
2023-12-31	-0.99	-0.99
2023-09-30	-1.08	-1.09
2023-06-30	-1.45	-1.44
2023-03-31	-2.28	-2.27
2022-12-31	-0.41	-0.41
2022-09-30	-0.79	-0.79
2022-06-30	-0.87	-0.86
2022-03-31	-0.96	-0.96
2021-12-31	-0.96	-0.96
2021-09-30	-0.85	-0.86
2021-06-30	-0.92	-0.92
2021-03-31	-0.87	-0.87
2020-12-31	-0.76	-0.76
2020-09-30	-0.85	-0.86

Cash Flow: Operations, Investing, Financing

The cash from operating activities for Summit Therapeutics Inc. as of June 30, 2025 is -206.88 MM.
The cash from investing activities for Summit Therapeutics Inc. as of June 30, 2025 is 285.79 MM.
The cash from financing activities for Summit Therapeutics Inc. as of June 30, 2025 is 190.43 MM.

Period End (TTM)	Cash From Operating Activities (MM)	Cash From Investing Activities (MM)	Cash From Financing Activities (MM)
2025-06-30	-206.88	285.79	190.43
2025-03-31	-173.14	-65.10	388.42
2024-12-31	-142.11	-205.34	381.23
2024-09-30	-112.89	-228.25	411.09
2024-06-30	-97.49	-123.13	207.18
2024-03-31	-93.76	77.16	6.89
2023-12-31	-76.76	-587.77	86.51
2023-09-30	-52.11	-648.33	600.32
2023-06-30	-45.77	-644.83	675.09
2023-03-31	-35.71	-645.33	675.17
2022-12-31	-41.58	-0.62	620.24
2022-09-30	-55.95	-0.75	101.44
2022-06-30	-70.96	-0.77	27.12
2022-03-31	-70.92	-0.63	47.21
2021-12-31	-72.59	-0.31	77.92
2021-09-30	-71.38	-0.24	127.20
2021-06-30	-64.46	-0.28	126.53
2021-03-31	-63.82	-0.27	106.44
2020-12-31	-48.11	-0.42	50.55
2020-09-30	-48.92	-0.39	29.50

Valuation Metrics : PE, PriceToBook, PriceToTBV

The p/e for Summit Therapeutics Inc. as of June 30, 2025 is -65.58.
The p/book for Summit Therapeutics Inc. as of June 30, 2025 is 45.85.
The p/tbv for Summit Therapeutics Inc. as of June 30, 2025 is 46.11.

P/Book: The current closing price divided by the book value per share.

P/TBV: The current price divided by the tangible book value per share.

Period End (TTM)	p/e	P/Book	P/TBV
2025-06-30	-65.58	45.85	46.11
2025-03-31		38.56	38.75
2024-12-31	-67.09	30.13	30.26
2024-09-30	-96.29	79.82	80.59
2024-06-30	-47.58	124.96	130.50
2024-03-31	-4.28	33.87	34.72
2023-12-31	-3.07	18.44	18.78
2023-09-30	-2.14	10.68	10.85
2023-06-30	-2.92	13.12	13.30
2023-03-31	-15.41	9.58
2022-12-31		6.72	7.24
2022-09-30		4.63	5.85
2022-06-30	-1.05	1.50	1.84
2022-03-31	-2.69	2.86	3.36
2021-12-31	-3.50	2.57	2.93
2021-09-30	-6.69	7.61	9.57
2021-06-30
2021-03-31	-2.29	2.28	2.88
2020-12-31	-2.77	1.84	2.22
2020-09-30	-2.34	3.23	5.08

Valuation Metrics : EBitToEv, EBit3YrAvgToEv

The ebit/ev for Summit Therapeutics Inc. as of June 30, 2025 is -0.02.
The ebit (3y)/ev for Summit Therapeutics Inc. as of June 30, 2025 is -0.02.

Period End (TTM)	EBIT/EV	EBIT (3y)/EV
2025-06-30	-0.02	-0.02
2025-03-31	-0.02	-0.02
2024-12-31	-0.01	-0.02
2024-09-30	-0.01	-0.02
2024-06-30	-0.02	-0.05
2024-03-31	-0.22	-0.09
2023-12-31	-0.30	-0.13
2023-09-30	-0.45	-0.19
2023-06-30	-0.33	-0.14
2023-03-31	-0.06	-0.06
2022-12-31	-0.11	-0.09
2022-09-30	-0.41	-0.34
2022-06-30	-2.09	-1.54
2022-03-31	-0.53	-0.36
2021-12-31	-0.41	-0.28
2021-09-30	-0.19	-0.13
2021-06-30
2021-03-31	-0.65	-0.29
2020-12-31	-0.66	-0.28
2020-09-30	-0.52	-0.20

Management Effectiveness

The roa for Summit Therapeutics Inc. as of June 30, 2025 is -0.70.
The roe for Summit Therapeutics Inc. as of June 30, 2025 is -1.23.
The roic for Summit Therapeutics Inc. as of June 30, 2025 is -0.69.
The croic for Summit Therapeutics Inc. as of June 30, 2025 is 0.43.
The ocroic for Summit Therapeutics Inc. as of June 30, 2025 is -0.49.

Period End (TTM)	ROA	ROE	ROIC	CROIC	OCROIC
2025-06-30	-0.70	-1.23	-0.69	0.43	-0.49
2025-03-31	-1.25	-5.01	-0.53	0.08	-0.34
2024-12-31	-0.97	-2.53	-0.42	0.15	-0.24
2024-09-30	-0.74	-1.63	-0.40	-0.03	-0.24
2024-06-30	-0.46	-0.87	-0.76	-0.06	-0.61
2024-03-31	-0.93	-4.86	-2.17	-2.03	-0.27
2023-12-31	-3.85	-4.48	-1.95	-0.32	-0.17
2023-09-30	-6.24	-11.65	-2.63	-0.07	-0.20
2023-06-30	-6.27	-11.69	-2.42	-0.06	-0.19
2023-03-31	-0.68	-1.22	-0.92	-0.01	-0.05
2022-12-31	-0.67	-0.85	-0.53	0.26	-0.34
2022-09-30	-0.66	-0.83	-0.53	0.26	-0.34
2022-06-30	-0.64	-1.44	-1.08	-0.59	-0.91
2022-03-31	-0.63	-1.38	-1.38	-0.37	-1.06
2021-12-31	-0.73	-2.04	-1.03	0.06	-0.69
2021-09-30	-1.32	-1.99	-0.72	0.57	-0.97
2021-06-30	-1.02	-1.08	-0.60	0.55	-0.53
2021-03-31	-0.89	-1.17	-0.53	0.39	-0.53
2020-12-31	-0.55		-1.41	0.07	-1.29
2020-09-30	-1.05	-1.51	-1.34	-0.56	-1.29

Gross Margins

Gross Margin: The Gross Margin is the ratio of revenue left after substracting the Cost of Goods Sold. It is calculated as 1.0 - (Revenue - COGS ) / Revenue.

Net Margin: The Net Margin (aka Profit Margin) is the ratio of revenue left after substracting the Net Income. It is calculated as Net Income / Revenue.

Operating Margin: The Operaing Margin is the ratio of revenue left after substracting the Operating Income. It is calculated as Operating Income / Revenue.

Period End (TTM)	Gross Margin	Net Margin	Operating Margin
2025-06-30
2025-03-31
2024-12-31
2024-09-30
2024-06-30
2024-03-31
2023-12-31
2023-09-30	1.00	-2,716.85	-282.13
2023-06-30	1.00	-2,716.85	-282.13
2023-03-31	1.00	-1,318.16	-129.60
2022-12-31	1.00	-90.64	-81.42
2022-09-30	1.00	-90.64	-81.42
2022-06-30	1.00	-41.50	-39.31
2022-03-31	1.00	-49.55	-48.97
2021-12-31	1.00	-48.98	-47.64
2021-09-30	1.00	-43.05	-41.13
2021-06-30	1.00	-119.00	-111.04
2021-03-31	1.00	-87.98	-82.30
2020-12-31	1.00	-61.28	-60.85
2020-09-30	1.00	-2.28	-2.48